
CNTX Stock Forecast & Price Target
CNTX Analyst Ratings
Bulls say
Context Therapeutics Inc is demonstrating a strong trajectory in its clinical development, particularly with the promising early data from its CTIM-76 program, which highlights favorable safety profiles and initial efficacy in heavily pre-treated patients. The company's robust financial positioning, with an extended cash runway into 2027, supports its ongoing development efforts across multiple assets, enhancing its potential for near-term value catalysts. Furthermore, the unique mechanism of CTIM-76, targeting CLDN6 with high potency, positions Context Therapeutics favorably against competitors, with the potential to attract partnerships and generate investor interest ahead of more traditional data releases.
Bears say
Context Therapeutics Inc. demonstrated a significant reduction in research and development expenses, with a decline from $16.8 million in Q3 2024 to $8.7 million in Q3 2025, driven by the absence of prior in-process charges. Despite this reduction, the company reported a net loss of $9.7 million in Q3 2025, down from $17.5 million the previous year, indicating ongoing financial challenges. Furthermore, the company faces several risks such as the need for approximately $250 million in additional financing by 2041, potential safety and efficacy uncertainties in its clinical programs, and risks of delisting due to inadequate stock performance and low trading volume.
This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.
CNTX Analyst Forecast & Price Prediction
Start investing in CNTX
Order type
Buy in
Order amount
Est. shares
0 shares